AKBLF Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 20.52% compared to ALK-Abello A/S's net margin of -64.14%. ALK-Abello A/S's return on equity of 19.36% beat Evaxion AS's return on equity of --.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 170%. Given that Evaxion AS has higher upside potential than ALK-Abello A/S, analysts believe Evaxion AS is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.690, which suggesting that the stock is 30.968% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $239.5M, which are larger than Evaxion AS quarterly revenues of $37.5K. ALK-Abello A/S's net income of $49.2M is higher than Evaxion AS's net income of -$4.9M. Notably, ALK-Abello A/S's price-to-earnings ratio is 48.90x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.87x versus 3.52x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab A/S has a net margin of 20.52% compared to ALK-Abello A/S's net margin of 39.24%. ALK-Abello A/S's return on equity of 19.36% beat Genmab A/S's return on equity of 28.3%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Genmab A/S has an analysts' consensus of $37.24 which suggests that it could grow by 17.34%. Given that Genmab A/S has higher upside potential than ALK-Abello A/S, analysts believe Genmab A/S is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.690, which suggesting that the stock is 30.968% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.809%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $239.5M, which are smaller than Genmab A/S quarterly revenues of $1B. ALK-Abello A/S's net income of $49.2M is lower than Genmab A/S's net income of $399.2M. Notably, ALK-Abello A/S's price-to-earnings ratio is 48.90x while Genmab A/S's PE ratio is 13.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.87x versus 5.56x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

IO Biotech, Inc. has a net margin of 20.52% compared to ALK-Abello A/S's net margin of --. ALK-Abello A/S's return on equity of 19.36% beat IO Biotech, Inc.'s return on equity of -297.46%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand IO Biotech, Inc. has an analysts' consensus of $2.46 which suggests that it could grow by 253.57%. Given that IO Biotech, Inc. has higher upside potential than ALK-Abello A/S, analysts believe IO Biotech, Inc. is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.690, which suggesting that the stock is 30.968% less volatile than S&P 500. In comparison IO Biotech, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. IO Biotech, Inc. pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $239.5M, which are larger than IO Biotech, Inc. quarterly revenues of --. ALK-Abello A/S's net income of $49.2M is higher than IO Biotech, Inc.'s net income of -$8.4M. Notably, ALK-Abello A/S's price-to-earnings ratio is 48.90x while IO Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.87x versus -- for IO Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 20.52% compared to ALK-Abello A/S's net margin of 26.68%. ALK-Abello A/S's return on equity of 19.36% beat Novo Nordisk A/S's return on equity of 68.76%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.27 which suggests that it could grow by 11.31%. Given that Novo Nordisk A/S has higher upside potential than ALK-Abello A/S, analysts believe Novo Nordisk A/S is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.690, which suggesting that the stock is 30.968% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.61% to investors and pays a quarterly dividend of $0.58 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ALK-Abello A/S quarterly revenues are $239.5M, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. ALK-Abello A/S's net income of $49.2M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, ALK-Abello A/S's price-to-earnings ratio is 48.90x while Novo Nordisk A/S's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.87x versus 4.57x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.